Skeletal muscle can adapt to various stimuli. Physical activity and exercise represent different types of stresses to the muscle.
READ MORE >
Immuno-Oncology drugs are considered as a breakthrough in cancer treatment because of their ability to target and enable immune cells
Despite millions of sufferers around the world and the market valued at over $3.5 billion a year, osteoarthritis..
Glioblastoma (GBM) is the aggressive and most common form of brain cancer. The efficient treatment of GBM…
Latest updates on the use of Gd enhanced MRI in clinical research and clinical trials.
Advanced imaging & quantitative biomarkers offer the opportunity to provide sensitive and specific tumour measurements.
There are three types of AI being deployed by life science businesses, which can provide a framework for improving efficiencies.
Understanding how osteoarthritis (OA) clinical development paradigms might change….
Adopting to a digital mind-set in a clinical setting is a new business imperative for #investors, #biotech and #pharma
Investment in immuno-therapies will be reliant on biomarkers rather than patient survival rate.
Imaging de-risks critical decisions in clinical drug development.
Increasing use of technology in lifesciences transforming pharma and tech giants.
Precision Medicine through Nuclear Medicine and Molecular Imaging
Advanced imaging and methodologies for image analysis are changing precision medicine and patient phenotyping.
Success of oncology drug development lays in early insight into tumor signature or the microstructural phenotype.
Advanced image assessment, AI-driven biomarkers and the disruptive potential of integrating AI into the drug development process.
Future of speedy decisions and fast outcomes depends on our ability to challange the computing status-quo.
Comprehensive review of the modern imaging and quantitative assessments in OA weight loss.
Radiogenomics: A novel technique offering a non-invasive approach to glioblastomas characterization.
Technology. Innovation. Shifting world. Where are biopharmaceuticals heading?
Bio-pharma R&D focus in the post-covid aftermath.
How lifescience industry is saving the world: covid vs science.
When it comes to drug development, what is essential?
Cell & Gene Therapy vs rare, incurable and inherited genetic diseases.
Impact of technology and AI into drug development.
Optimizig phase R&D today and post-covid – thoughts, trends and predictions
Impact of Imaging, technology & AI in Drug Development for Rheumatic Diseases.
IAG’s vision: following Annual Scientific Meeting of the Society for Neuro-Oncology.
View on the growing technology need in drug development in 2021 and beyond.
Central imaging in successful oncology clinical trials.
Why embracing digital transformation in drug development is the Leader’s’ job.
Increase the scientific value of clinical trials and accelerate the drug to market process.
Artificial Intelligence advancing clinical studies.
The world saw unprecedented growth in healthcare investing in 2021.
While studying for her PhD at Leeds, UK Olga Kubassova began work on commercialising her research.
Breakthroughs in AD research and trials rely on accurate imaging and its interpretation.
Thinking through drug approval: the FDA and EMA and their requirements.
Critical Role of Imaging is Crucial in Drug Development
The field of bone health is undergoing unprecedented advancements, with novel imaging techniques deployed to take novel platforms through approvals.
Share IAG’s experience in using Medical Imaging and A.I. in early and late phase clinical trials.
